To develop a mapping model for estimating sixdimensional health state short form (SF-6D) utility scores from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (QLQ-C30 and QLQ-CR29) scores in patients with colorectal cancer (CRC), with and without adjustment for clinical and demographic characteristics. Methods: Ordinary least squares regression models were applied to a cross-sectional data set of 216 patients with CRC collected from a regional hospital in Hong Kong. Item responses or scale scores of cancer-specific (QLQ-C30) and colorectal-specific health-related quality-of-life (QLQ-CR38/ CR29) data and selected demographic and clinical characteristics of patients were used to predict the SF-6D scores. Model goodness of fit was examined by using exploratory power (R 2 and adjusted R 2 ), Akaike information criterion, and Bayesian information criterion, and predictive performance was evaluated by using root mean square error, mean absolute error, and Spearman's correlation coefficients between predicted and observed SF-6D scores. Models were validated by using an independent data set of 56 patients with CRC. Results: Both scale and item response models explained more than 67% of the variation in SF-6D scores. The best-performing model based on goodness of fit (R 2 ¼ 75.02%), predictive ability in the estimation (root mean square error ¼ 0.080, mean absolute error ¼ 0.065), and validation data set prediction (root mean square error ¼ 0.103, mean absolute error ¼ 0.081) included variables of main and interaction effects of the QLQ-C30 supplemented by QLQ-CR29 subset scale responses and a demographic (sex) variable. Conclusions: SF-6D scores can be predicted from QLQ-C30 and QLQ-CR38/CR29 scores with satisfactory precision in patients with CRC. The mapping model can be applied to QLQ-C30 and QLQ-CR38/ CR29 data sets to produce utility scores for the appraisal of clinical interventions targeting patients with CRC using economic evaluation.
Introduction
Under the constraints of resource limitations, health policy makers usually allocate available resources among health interventions on the basis of their clinical performances. This does not, however, take cost and comparable benefit into account, meaning that the allocation of resources may be suboptimal. Colorectal cancer (CRC) impacts a heavy economic burden of disease in the world because of its relatively high incidence rates and treatment costs [1] . Cost-utility analysis is conducted by using the cost per quality-adjusted life-year (QALY) gained to critically appraise the emerging alternatives of costly therapies and interventions for CRC. The QALYs for each CRC health state can be calculated by using direct elicitation methods involving the use of standard gamble or time trade-off techniques [2] [3] [4] [5] or and multidimensions of HRQOL in the oncology field: the Functional Assessment of Cancer Therapy-General (27 items) [12] and the EORTC Core Quality of Life Questionnaire (QLQ-C30, 30 items) [13] . In addition to cancer-specific HRQOL measures, the Functional Assessment of Cancer Therapy-Colorectal [14] and EORTC Colorectal Cancer-specific Quality of Life Questionnaire (QLQ-CR38, 38 items) [15] are widely used colorectal-specific HRQOL measures. The Chinese versions of all aforementioned questionnaires have been validated in Hong Kong Chinese patients [16, 17] . The QLQ-CR38 was superseded by the QLQ-CR29, which was an updated and improved version of the colorectal-specific measure [18] .
The majority of mapping functions available used the EQ-5D questionnaire as their target measure [11] , probably due to the preference for the use of the EQ-5D questionnaire in technology appraisals submitted to the National Institute for Health and Clinical Excellence [10] . Eight studies [19] [20] [21] [22] [23] [24] [25] [26] used QLQ-C30 data to predict EQ-5D questionnaire utility scores but only one study mapped the EORTC QLQ-C30 to SF-6D utility score derived by using the UK value set [25] . No mapping function for the EORTC QLQ-C30 has ever been done in Chinese populations. Health preference varies systematically across countries because of cultural differences, and therefore preference weighting of preference-based measures is preferably based on local population valuations. The SF-6D is the only multiattribute classification system that has a preference weighting algorithm specific to the Chinese population [27] , which makes mapping functions targeting to SF-6D more applicable and valid in our setting.
Despite the evidence that the development of mapping functions was frequently built on patients with cancer condition [28] , none of them was specific to patients with CRC. Although numerous studies have developed mapping functions that predicted utility scores by using QLQ-C30 data across a range of different cancer patients groups [19] [20] [21] [22] [23] [24] [25] [26] 29] , no study has mapped from the EORTC CRC-specific module (QLQ-CR38 and QLQ-CR29) to any preferencebased measure. Since then, the primary aim of this study was to map from the EORTC cancer-specific and CRC-specific scale scores or item responses to SF-6D preference-based utility scores in patients with different stages of CRC, adjusting for demographic factors. This mapping function enabled researchers to conduct health economic appraisals of population-based screening and treatment modalities for CRC where data have been collected only by using non-preference-based cancer-specific measures.
Methods

Subjects
This study was a secondary analysis of data obtained from a health survey to examine the HRQOL profile and preference-based scores of patients with colorectal neoplasms in a Chinese population [16, [30] [31] [32] . Study data were obtained from a cross-sectional survey of 587 adult patients attending the colorectal specialist outpatient clinic of an academic teaching hospital in Hong Kong between October 2009 and July 2010. Data of 272 patients with known staged CRC (using the American Joint Committee on Cancer classification) who had completed the cancer-specific QLQ-C30, CRC-specific QLQ-CR38, and generic SF-6D instruments were separated into two samples, one (self-administration ¼ 216, 79.4%) for model development and the other (interviewer-administration ¼ 56, 20.6%) for model validation.
HRQOL Measures
EORTC Measure
The Traditional Chinese version 3 of the QLQ-C30 is a cancerspecific HRQOL instrument [13, 17] that has a global health status and quality-of-life scale (QL), five functional scales (physical functioning, PF; role functioning, RF; emotional functioning, EF; cognitive functioning, CF; and social functioning, SF), and nine symptom scales/items (fatigue, FA; nausea and vomiting, NV; pain, PA; dyspnea, DY; insomnia, SL; appetite loss, AP; constipation, CO; diarrhea, DI; and financial difficulties, FI) specific to cancer. The QL scale of the QLQ-C30 consists of two items measuring the degree to which the overall quality of life was subjectively perceived by patients, using a seven-point Likert scale ranging from 1 ¼ ''Very poor'' to 7 ¼ ''Excellent.'' All items in other scales are scored by using a four-point Likert scale (1 ¼ ''Not at all,'' 2 ¼ ''A little,'' 3 ¼ ''Quite a bit,'' and 4 ¼ ''Very much''). To facilitate mapping from the existing data set containing QLQ-C30 only, mapping functions were estimated by using 30 items of the QLQ-C30 as explanatory variables. Moreover, the CRC-specific QLQ-CR38 encompasses four functional scales and seven symptom scales or items [15] . Both colorectal-specific QLQ-CR38 and QLQ-CR29 are additional questionnaire modules that require supplemental use in conjunction with the QLQ-C30. In an attempt to make the mapping functions applicable to utilization in data sets containing either QLQ-CR38 or QLQ-CR29, mapping functions were estimated by using 30 items of the QLQ-C30 plus only the 10 items of the QLQ-CR38 as explanatory variables. Those items have the same wording or phrase as the corresponding QLQ-CR29 items [18] labeled as QLQ-CR29 subset , representing two functional scales (body image, BI; anxiety, ANX) and five symptom scales/items (urinary frequency, UF; dysuria, DYSU; abdominal pain, APAIN; bloating, BF; and dry mouth, DM). Their content validity was supported by a study on patients with CRC who rated these items relevant and acceptable [33] .
The raw score of each scale is summed and rescaled to range from 0 to 100, according to the standardized EORTC scoring guidelines [34] . Higher scores in global and functional scales but lower scores in symptom scales indicate better HRQOL.
SF-6D
The SF-6D is a widely used preference-based generic HRQOL measure with a multiattribute classification system consisting of six dimensions: physical functioning, role functioning, social functioning, pain, mental health, and vitality. Each dimension is composed of three to five levels. The health status described by the combination of six dimensional attributes was converted into an SF-6D value by applying preference weights derived from the general population. Population-specific SF-6D preference weights had been elicited in the United Kingdom [7] , our local Hong Kong Chinese population [27, 35] , and other populations [36, 37] . The Hong Kong weights were used in the current study. The Hong Kong population SF-6D values range from 0.315 to 1, with higher scores indicating better HRQOL anchoring on the 0 (dead) to 1 (full health) scale.
Statistical Analysis
Model Development and Specifications
Therefore, 12 model specifications were estimated, where SF-6D was regressed on S1) QLQ-C30 scale scores, S2) as per S1 plus squared and pair-wise interaction terms, S3) as per S2 plus demographic and clinical variables, S4) QLQ-C30 and QLQ-CR29 subset scale scores, S5) as per S4 plus squared and pair-wise interaction terms, S6) as per S5 plus demographic and clinical variables, R1) QLQ-C30 raw responses, R2) as per R1 plus squared and pair-wise interaction terms, R3) as per R2 plus demographic and clinical variables, R4) QLQ-C30 and QLQ-CR29 subset raw responses, R5) as per R4 plus squared and pair-wise interaction terms, and R6) as per R5 plus demographic and clinical variables. To ensure direct comparability of different models, only cases (n ¼ 216) with complete data of all variables involved in the modeling process were used throughout the analysis.
Multiple regression analyses were used to establish the prediction models of SF-6D in forward stepwise selection approach. Initially, the SF-6D score was regressed on the main effects of the scale scores. Only those significant variables were retained in the next model. Significant squared and pair-wise interaction terms of the selected scale scores were added to the model to account for possible nonlinearity. Because of the principle of hierarchy, the corresponding lower-order main effect terms must be retained in the model even if their coefficients became insignificant. In the final model, three clinical variables of American Joint Committee on Cancer (AJCC) cancer staging, treatment active, and stoma and two demographic variables of sex and age were added as explanatory variables. The F test was used to determine which variables to retain with an inclusion criterion of P value lower than 0.05 and exclusion criterion of P value greater than 0.10. If the P value of any second-order term added in the former phases exceeded 0.10 in a later model, the term would be removed from the model process but would be considered for reentry in the final model. The analysis was repeated by using the QLQ-C30 and QLQ-CR29 subset items as explanatory variables. The data set had good coverage of possible responses to SF-6D, QLQ-C30, and QLQ-CR29 subset , where only four items did not have responses across every severity level (level 1 of Q29 and Q30, level 4 of Q14 and Q15 [see . For items with a low number (o5%) of responses at the most extreme level, responses were merged with the adjacent level unless the item had two levels.
Ordinary least squares estimation is most widely used for the development of mapping models [11] . In recent years, there has been an increasing interest in the use of different model types that are more appropriate for the distribution of EQ-5D questionnaire data, which is bi-or trimodal, with typically a large percentage of responses at 1. Although the Kolmogorov-Smirnov test failed to show the normal distribution of SF-6D based on samples of model development (P o 0.001) and validation (P o 0.001), the test was typically sensitive to reject the null hypothesis. Figure 1 illustrates SF-6D distribution on the basis of data of model development and validation, meaning that ordinary least squares is appropriate, and it was therefore used in this article. The ordinary least squares model is basically characterized as the unbiased estimation of parameters if the assumption on homogeneity of residual variance holds. The residual plots for the final models were used as the primary tool to examine the model adequacy such as the nonnormality and heteroscedasticity within the data.
Model Validation and Comparison
Model goodness of fit was assessed by R 2 and adjusted R 2 statistics, Akaike information criteria (AIC), and Bayesian information criteria (BIC) statistics. R 2 and adjusted R 2 statistics measured the explanatory power of a model, that is, how much of the variability in the dependent variable can be explained by the predictors. The goodness of fit was also described by using AIC and BIC statistics, with the lower values indicating better fit. Spearman's correlation coefficients (r) and intraclass correlation coefficients were calculated to assess the relationship between predicted and observed SF-6D scores. To further assess the predictive ability of a model, the differences between the predicted and observed SF-6D scores at the individual level were examined by computing root mean square error (RMSE) and mean absolute error (MAE). In addition, the number of observations and the corresponding proportions in the sample where the absolute error was greater than 0.05 and 0.10, respectively, were calculated. The ranges of the achievable SF-6D scores from the resulting mapping functions were compared with the range of the SF-6D scores computed by the standard algorithm.
To assess the predictive performance of the mapping functions, an out-of-sample validation was performed by using QLQ-C30, QLQ-CR29 subset , and SF-6D data from the validation data set, which was not used for model development. The mapping functions developed in this article were used to produce predicted SF-6D scores, and the predictive ability of the models was explored by comparing predicted and observed SF-6D scores by using both the model development sample and an out-of-sample validation data set. These results were compared with predictions obtained by applying an existing SF-6D mapping function created by Kontodimopoulos et al. [25] .
All regressions and other analyses were conducted by using SPSS version 20.0 (SPSS, IBM, Inc., Chicago, IL, USA).
Results
Descriptive Statistics for SF-6D and EORTC
Demographic and clinical characteristics of patients are shown in Table 1 . The model development and validation groups were statistically different for age, sex, education level, marital status, and working status but not in clinical characteristics. Table 2 shows the observed SF-6D, QLQ-C30, and QLQ-CR29 subset scale of the model development and validation groups. Mean SF-6D score was statistically different, but most QLQ-C30 and QLQ-CR29 subset scale scores did not differ across groups. The observed range of SF-6D and most of the QLQ-C30 and QLQ-CR29 subset scale scores were the same as the possible range in the model development group while these ranges were narrower than the possible range in the model validation group. No floor effect was observed in SF-6D in both groups, but there was a slight ceiling effect, with 6.6% of the subjects having an upper bound of 1 in both samples. The global health status and functional scale scores of QLQ-C30 scales and functional scale scores of QLQ-CR29 subset scales had a ceiling effect (420%), and symptom scale scores of QLQ-C30 scales and QLQ-CR29 subset scales had a floor effect (420%) in both groups.
Regression Models Using Scale Scores
Regression models and their goodness of fit are summarized in Table 3a and Table 3b . Significant variables in the models using the QLQ-C30 scale were slightly different from models using the QLQ-C30 supplemented with the QLQ-CR29 subset . The main-effect terms selected from the QLQ-C30 scale scores in model S1 were QL, PF, EF, SF, FA, PA, and DI scale scores. Then, the square term of SF and the two interaction terms of PF Â EF and FA Â EF were added in model S2. The influence of the main-effect terms of PF and SF, however, changed to not significant after the square terms and interactions terms were added to S2. All clinical and demographic factors were not significant (model not shown). When selecting scale scores from the QLQ-C30 supplemented with the QLQ-CR29 subset , the SF scale was replaced by the BI scale in the main-effects term in model S4. Then, the square term of DI and the two interaction terms of PF Â BI and QL Â EF were included but the main-effect terms of QL, PF, EF, and BI were insignificant in model S5. Model S6 also included the demographic variable of sex.
Regression Models Using Item Responses
Regression models and their goodness of fit are summarized in Table 4a and Table 4b . Significant variables were similar for models estimated by using QLQ-C30 data only and models using QLQ-C30 data supplemented with the QLQ-CR29 subset . In the first model R1, the main-effect terms selected from the QLQ-C30 were PF(Q2 and Q5), FA(Q12 and Q18), SF(Q26), and QL(Q30) scales. For model R4 estimated by using QLQ-C30 and QLQ-CR29 subset data, the main-effect terms of PA(Q9), SF(Q27), and BI(Q46) were added but SF(Q26) and QL(Q30) were excluded. In models R2 and R5, the interaction term PF(Q2) Â FA(Q18) was added but variable FA(Q18) 
Comparison Across All Models
The best models using scale and item responses were S6 and R6, respectively. (See SPSS syntax Appendices 2 and 3 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2012.12. 004.) The PF and FA scale scores were significant in the scale models, and those underlying items were significant in item responses models. Models R6 and S6 differed in their model specifications because S6 included all main-effect variables whereas R6 retained only significant items. However, the scales that had significant variables varied across the two models. In model R6, main effects for FA, PA, and DI were significant, whereas in model S6, items from scales of PF, PA, FA, SF, and BI were significant. Predictive performance was similar in models S6 and R6. For example, Spearman's correlation coefficients were about 0.87, and the RMSE and MAE were 0.08 and around 0.07 respectively, indicating low extent of predictive error with high level of accurate predictions. In addition, Table 5 demonstrates the differences between the predicted and observed SF-6D scores.
There was overprediction for more severe health states when the observed SF-6D score was smaller than 0.7 and vice versa (Fig. 2) .
With regard to goodness of fit, however, model S6 yielded highest adjusted R 2 , AIC, and BIC among all models. Table 6 shows the predictive performance of the models using the out-of-sample validation data set. For all models, ME ranged from 0.045 to 0.063. RMSE and MAE were approximately 0.10 and 0.08 in all models except the QLQ-C30 item response models R1 to R3, which had a slightly larger value of 0.115 to 0.128 and 0.095 to 0.102, respectively. Spearman's correlation coefficients were around 0.8 and 0.7 in the scale and item response models, respectively, indicating high associations between the predicted and observed SF-6D scores. Correlation was high for Kontodimopoulos's predictions, but predictive performance was much poorer. Although the Spearman's correlation coefficient was the greatest between observed SF-6D scores and predicted SF-6D scores produced using the Kontodimopoulos's model, the ME, RMSE, and MAE were above 0.3 and the proportion of subjects with an absolute error of more than 0.05 was more than 95%.
Model Validation
Discussion
This study predicted SF-6D utility scores by using both item responses and scale scores of the QLQ-C30 and QLQ-CR29 subset measures in patients with CRC. Models containing the QLQ-C30 scale and QLQ-CR29 subset item response scores fitted satisfactorily on the basis of commonly reported statistical indicators (R 2 and adjusted R 2 ), with exploratory power achieving at least 67% [11] . The mapping models described in this article had better performance than did mapping models we recently developed from Functional Assessment of Cancer Therapy-General or Functional Assessment of Cancer Therapy-Colorectal subscale scores on the basis of patients with colorectal neoplasms (including polyps) in terms of exploratory power and predictive performance [30] . Models estimated by using item responses had superior exploratory power and predictive performance to models estimated from scale scores only. Conversely, AIC and BIC information criterions for item response models were generally worse (less negative) than those of scale models. An interesting pattern for information criterions was observed among item models because an increased number of independent variables led to positive changes in the information criterions, suggesting that the simpler models with fewer variables are preferred. The addition of the QLQ-CR29 subset measure provided a larger number of functional and symptom variables for consideration, but it did not always lead to improved model performance and considerable increase in R 2 and adjusted R 2 . Although model S4 including the main effect of QLQ-C30 and QLQ-CR29 subset scale scores had the highest Spearman's correlation coefficient and lowest RMSE using the validation out-of-sample data set, the most preferred and best-performing model in terms of predictive performance was model S6, which included the main and interaction effects of QLQ-C30 and QLQ-CR29 subset scale scores plus sex variable.
Of particular interest was whether the inclusion of demographic variables as explanatory variables improved model performance. Previous studies found that age was a significant independent variable when mapping QLQ-C30 to the EQ-5D questionnaire [20, 26, [38] [39] [40] , but the results of this study did not find age to be statistically significant when predicting SF-6D scores. The significance of age found in other studies could be related to the type of cancer or the age range of the populations included in the model development studies. Sex was significant in two studies mapping QLQ-C30 to the EQ-5D questionnaire [20, 39] but not in one other study [38] . Our results found that the 
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A review of the literature on mapping QLQ-C30 to the EQ-5D questionnaire shows that 7 of 10 models had an R 2 of 49% to 80%, to which our models with an R 2 of 69% to 76% are comparable. The predictive performance of our models is better than that of existing models mapping QLQ-C30 to SF-6D. This may be because our development and validation data sets were all from CRC while existing models used data from a variety of cancer types, cancer stages, and cultures based on patients in different countries.
Studies mapping to the EQ-5D questionnaire often found models overpredicted better health states but underpredicted poorer health states, as indicated using graphs showing observed and predicted preference-based scores [19, 22, 30, 38, 40, [42] [43] [44] [45] [46] [47] . The pattern was different in our model mapping QLQ-C30 and QLQ-CR29 subset to SF-6D in that the largest errors were observed in SF-6D scores between 0.601 and 0.700, although errors were in general higher for more severe health states.
Limitations
This study had several limitations. First, sample size was insufficient to explore models including dummy variables for each level of every EORTC QLQ-C30 and QLQ-CR29 subset item, but these models were likely to suffer from multicollinearity. Model estimations using response mapping [48] and probabilistic mapping Fig. 2 -The scatter plot of mean observed and predicted SF-6D preference-based values by the health state ranking in descending order of the mean observed values. SF-6D, six-dimensional health state short form. [49] were not estimated although patients reported their health by using the SF-6D dimensions directly. There were not sufficient samples in all levels of SF-6D. Further research is encouraged to determine whether response mapping and probabilistic mapping are better approaches for mapping to SF-6D scores. Second, regression models were primarily validated by using interviewer-administered EORTC and SF-6D data, whereas the models were developed by using self-administered data. We assumed measure invariance between interviewer-and self-administration of measures in this article, but this is questionable based on a study on the colorectal-specific Functional Assessment of Cancer Therapy-Colorectal measure [50] . Further investigation on measurement invariance of the EORTC measure in respect to modes of administration is needed. However, validation on interviewer-administered data showed overall satisfactory model fit, suggesting that these models are robust for applications using either self-administered or intervieweradministered data. Finally, our subjects were all Chinese patients with CRC, recruited from one hospital in Hong Kong, which may not be fully representative of other Chinese populations. Extra caution should be taken when applying the mapping functions to non-Chinese or other disease groups. Therefore, further model validation of these mapping algorithms should be done by using data from patients with different ethnicity and types of cancer.
Conclusions
EORTC QLQ-C30 and QLQ-CR29 data can be successfully mapped onto SF-6D for Chinese patients with CRC. The models with the best predictive performance included sex and stoma variables. Models estimated by using scale or item responses performed similarly. The models were validated by using an out-of-sample data set. These models can be used to estimate SF-6D utility scores in the calculation of QALYs for future health economic evaluations when utility data were not collected.
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